저작자표시-비영리-변경금지 2.0 대한민국 이용자는 아래의 조건을 따르는 경우에 한하여 자유롭게 l 이 저작물을 복제, 배포, 전송, 전시, 공연 및 방송할 수 있습니다. 다음과 같은 조건을 따라야 합니다: l 귀하는, 이 저작물의 재이용이나 배포의 경우, 이 저작물에 적용된 이용허락조건 을 명확하게 나타내어야 합니다. l 저작권자로부터 별도의 허가를 받으면 이러한 조건들은 적용되지 않습니다. 저작권법에 따른 이용자의 권리는 위의 내용에 의하여 영향을 받지 않습니다. 이것은 이용허락규약(Legal Code)을 이해하기 쉽게 요약한 것입니다. Disclaimer 저작자표시. 귀하는 원저작자를 표시하여야 합니다. 비영리. 귀하는 이 저작물을 영리 목적으로 이용할 수 없습니다. 변경금지. 귀하는 이 저작물을 개작, 변형 또는 가공할 수 없습니다.
β
印
印
iii
-β
β
β
iv
-Keyword : Salmonella spp. Escherichia coli, Extended specturm β-lactamase, TEM, CTX-M14, CTX-M65
1 -β β β β β β β β β β β β β
2 -β β β β β β β β
4
6
-β
8
13
14
18
24
-1. 김군도 이훈구, . 부산 수영공공하수처리시설에서 분리된 광범위 항균제 베타 락탐 분해효소(Extended-Spectrum β-Lactamase, ESBL) 유형. The Korean Journal of Microbiology 2010, 46, 38-45.
2. 김윤태, 이훈구. 부산시내 종합병원에서의 임상검체에서 분리된 extended-spectrum β-lactamase 생성 Klebsiella pneumoniae 의 형별분류 한국. 미생물학회지 2000, 36, 221-227.
3. 성명숙 김진현 조재근 설성용 김기석, , , , . 국내 가금유래 병원성 대장균의 extended-spectrum β-lactamase (ESBL) 특성 조사. Korean J Vet res 2008, 48, 259-265.
4. 소정화. 국내 애완견에서 분리된 extended-spectrum β-lactamases (ESBLs) 및 AmlC β-lactamases 생성 E. coli 의 분자역학적 특성에 대한 분석. 2010, 서울대 학교 대학원 석사학위 논문.
5. 이경원 조성란 이창숙 정윤섭 권오현, , , , . Extended broad-spectrum β 생성
-lactamase Escherihia coli 와 Klebsiella pneumoniae. 감염 1994, 26, 341-348.
25
-(ESBL) Klebsiella 와 Enterobacter 의 유형. The Korean Journal of Microbiology 2001, 37, 277-283.
7. 이훈구. 부산 도축장에서 분리된 광범위 베타 락탐 분해효소 (Extended-Spectrum β-lactamase, ESBL) 생성 장내세균의 형별분류 한국미생물. 학회지 2006, 42, 125-130. 8. 조재근 김환득 권순효 김진현 장성일 박최규 김기석, , , , , , . 낙동강과 금호강에서 분리된 광범위 베타 락탐 분해효소 생성 Escherichia coli 내 항균제 내성 및 의 분포 한국가축위생학회지 integrons . 2014, 37, 19-27. 9. 조재근 성명숙 김진현 김기석, , , . 국내 가축 유래 대장균에서 CTX-M 및 TEM 형 extended-spectrum β-lactamases 의 검출 한국가축위생학회지. 2011, 34, 37-43.
10. Abraham EP and Chain. An enzyme from bacteria able to destroy penicillin. Nature 1940, 146, 837.
11. Alobwede I, Mzali FH, Livermore DM, Hentige J, Todd N, Hawkey PM. CTX-M extended spectrum beta lactamase arrives in UK. J. Antimicrob– – Chemother 2003, 51, 470-471.
26
-12. Baraniak A, Fiett J, Hryniewicz W, Nordmann P, Gniadkowski M. Ceftazidime-hydrolysing CTX-M-15 extended-spectrum beta-lactamase(ESBL) in Poland. J Antimicrob Chemother 2002, 50, 393-396.
13. Bauer AW, Kirby WMM, Sherris JC. Antibiotic susceptibility testing by a standized single disk method. Am J Clin Pathol 1966, 45, 493-496.
14. Beers MH. The Merck Manual of Medical Information 2nd Home Edition. Whitehouse Station, NJ, Merck, 2003.
15. Bonnet R. Growing group of extended spectrum: the CTX-M enzymes.Antimicrob Agent Chemother 2004, 48, 1-14.
16. Bradford PA. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat.Clin Microbiol Rev 2001, 14, 933 951.–
17. Brolund A, Edquist PJ, Makitalo B, Olsson-Liljequist B, Soderblom T, Wisell KT. Epidemiology of extendedspectrum beta-lactamase-producing Escherichia coli in Sweden 2007-2011. Clin Microbiol Infect 2014, 20, 344-352.
18. Brunton LL, Parker K, Blumenthal D. The goodman and gilman’s manual of pharmacological therapeutics. McGraw-Hill Professional, 2007.
27
-19. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for β -Lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother 1995, 39, 1211-1233.
20. Bush K. Extended-spectrum beta-lactamases in North America, 1987 2006.– Clin Microbiol Infect 2008, 14, 134 143.–
21. Canton R, Coque TM. The CTX-M beta-lactamase pandemic. Curr Opin Microbiol 2006, 9, 466-475.
22. Canton R, Novais A, Valverde A, Machado E, Peixe L, Baquero F. Prevalence and spread of extended-spectrum beta-lactamase-producing Enterobacteriaceae in Europe. Clin Microbiol Infect 2008, 14, 144 153.–
23. Chambers HF. Beta-Lactam & Other Cell Wall- & Membrane-Active Antibiotics. Basic & Clinical Pharmacology McGraw Hill, USA, 2007.
24. Choi MJ, Lim SK, Jung SC, Ko KS. Comparisons of CTX-M-producing
Escherichia coli Isolates from Humans and Animals South Korea. Journal of Bacteriology and Virology 2014, 44, 44-51.
25. Coque TM, Baquero F, Canton R. Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Euro Surveill 2008, 13, 19-51.
28
-26. Dallenne C, Costa AD, Decre D, Favier C, Arlet G. Development of a set of multiplex PCR assays for the detection of genes encoding important β -lactamases in Enterobacteriaceae. J Antimicrob Chemother 2010, 65, 490-495.
27. Datta N, Kontomichalou P. Penicillinase synthesis controlled by infectious R factor in Enterobacteriaceae. Nature 1965, 208, 239-244.
28. ECDC. EARSS annual report 2008. Bilthoven, the Netherlands: European Center for Disease Prevention and Control 2008, 64 82.–
29. Geroulanos S, Marathias K, Kriaras J, Kadas B. Cephalosporins in surgical prophylaxis. J Chemother 2001, 1, 23-26.
30. Ghuysen JM. Serine -Lactamases and penicillin binding proteins Annuβ Rev Microbiol 1991, 45, 37-67.
31. Giakkouple P, Tzouvelekis LS, Tsakris A, Loukova V, Sofianou D, Tzelepi E. IBC-1, a nouvel integron-associated class A β-lactamase with exteded-spectrum properties produced by an Enterobacter cloacae clinical strain. Antimicrob Agents Chemother 2000, 44, 2247-2253.
29
-LE, Struelens MJ. Antibiotic susceptibility among aerobic gram-negativebacilli in intensive care units in 5 European countries. French and Por-tuguese ICU Study Groups. JAMA 1999, 281, 67 71.–
33. Hoban DJ, Lascols C, Nicolle LE, Badal R, Bouchillon S, Hackel M. Antimicrobial susceptibility of Enterobacteriaceae, including molecular characterization of extended-spectrum beta-lactamase-producing species,in urinary tract isolates from hospitalized patients in North America and Europe: results from the SMART study 2009 2010. Diagn Microbiol InfectDis 2012,– 74, 62 67.–
34. Holten KB, Onuko EM. Appropriate prescribing of oral beta-lactam antibiotics. Am Fam Physician 2000, 62, 611-620.
35. Humeniuk C, Arlet G, Gautier V, Grimont P, Labia R, and Philippon A. Beta-lactamases of Kluyvera ascorbata, probable progenitors of some plasmidencoded CTX-M types. Antimicrob Agents Chemother 2002, 46, 3045-3049.
36. Ishii Y, Ohno A, Taguchi H, Imago S, Ishiguru M, Matsuzwa H. Cloning and sequence of the gene encoding a cefotaxime-hydrolyzing class A, β -Lactamase isolated from Escherichia coli. Antimicrob Agent Chemother 1995,
30
-39, 2269-2275.
37. Jacoby GA and Medeiros AA. More extended- spectrum β-Lactamase. Antimicrob. Agent Chemother 1991, 35, 1697-1704.
38. Jean SS, Hsueh PR. High burden of antimicrobial resistance in Asia. Int J Antimicrob Agents 2011, 37, 291 295.–
39. Jeong SH, Bae IK, Kwon SB, Lee JH, Jung HI, Song JS, Jeong BC, Kim SJ, Lee SH. Investigation of exteded-spectrum b-lactamases produced by clinical isolates of Klebsiella pneumoniae and Escherichia coli in Korea. Lett Microbiol 2004, 39, 41-47.
40. Jouvenot M, Deschaseaux ML, Royez M, Mougin C, Cooksey RC, Michel-Briand Y, and Adessi GL. Molecular hybridization versus isoelectric focusing to determine TEM type β-lactamases in gram-negative bacteria. Antimicrob Agents Chemother 1987, 31, 300-305.
41. Kim J, Lim YM, Jeong YS, Seol SY. Occurrence of CTX-M-3, CTX-M-15, CTX-M-14, and CTX-M-9 extended-spectrum β-lactamases in enterobacteriae clinical isolates in Korea. Antimicrob Agents Chemother 2005, 49, 1572-1575.
31
-CTX-M and SHV-12 B-lactamases are the most common extended-spectrum enzymes in clinical isolates of Escherichia coli and Klebsiella pneumoniae
collected from 3 university hospitals within Korea. FEMS Microbiol Lett 2005, 245, 93-98.
43. Kim YH, Joo IS, Kim YJ, Oh MH, Cho JI, Han MK, Kim SH, Moon TW, P KS. Detection of CTX-M type ESBL producing Salmonella in Retail Meat in Korea. J Fd Hyg Safety 2014, 29, 47-52.
44. Knothe H, Shah P, Krcmery V, Antal M, Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clini-cal isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 1983, 11, 315 317.–
45. Lee SH, Kim MN, Choi SJ, Chung WS. Chracteristics of extended-spectrum β-lactamases of Escherichia coli strains isolated from clinical specimens. Korean J Clin Pathol 2000, 20, 404-409.
46. Lewis MT, Yamaguchi K, Biedenbach DJ, Jones RN. In vitro evaluationof cefepime and other broad-spectrum beta-lactams in 22 medical centersin Japan: a phase II trial comparing two annual organism samples. TheJapan Antimicrobial Resistance Study Group. Diagn Microbiol Infect Dis 1999, 35,
32
-307-315.
47. Lim JS. The Characterization of E. coli Producing Extended-spectrum β -lactamase (ESBL) Isolated from Chicken Slaughterhouses in South Korea. 2014, A Thesis Submitted in Fulfillment for the Requirement of the Award of Master (MsC) of the Keonguk National University of Korea.
48. Lim SK, Lee HS, Nam HM, Jung SC, Bae YC. CTX-M-type beta-lactamase in Escherichia coli isolated from sick animals in Korea. Microb Drug Resist 2009, 15, 139-142.
49. Lu PL, Liu YC, Toh HS, Lee YL, Liu YM, Ho CM. Epidemiologyand antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009 2010 results fromthe Study for– Monitoring Antimicrobial Resistance Trends (SMART). Int J Antimicrob Agents 2012, 40, 37 43.–
50. Mshana SE. Molecular Epidemiology of Extended-Spectrum beta-Lactamases (ESBL) Producing Enterobacteriaceae from the Bugando Medical Centre, Mwanza, Tanzania and the University of Giessen Medical Hospital, Germany. 2011, A Thesis Submitted in Fulfillment for the Requirement of the Award of Doctor of Philosophy (PhD) of the St. Augustine
33
-University of Tanzania.
51. Naas T, Poirel L, Nordmann P. Minor extended-spectrum β-lactamases. Clin Microbiol Infect 2008, 14, 42-52.
52. Naseer U, Haldorsen B, Tofteland S, Hegstad K, Scheutz F, Simonsen GS. Molecular characterization of CTX-M-15-producing clinical isolates of
Escherichia coli reveals the spread of multidrug-resistant ST131 (O25:H4) and ST964 (O102:H6) strains in Norway. APMIS 2009, 117, 526-536.
53. Nuesch-IMT, Kayser FH, Hachler H. Survey and molecular genetics of SHV ß-lactamases in Enterobacteriaceae in Switzerland: two novel enzymes, SHV-11 and SHV-12. Antimicrob Agents Chemother 1997, 41, 943-949.
54. Olesen B, Hansen DS, Nilsson F, Frimodt MJ, Leihof RF, Struve C. Prevalence and characteristics of the epidemic multiresistant Escherichia coli
ST131 clonal group among extended-spectrum beta-lactamase-producing E. coli
isolates in Copenhagen, Denmark. J Clin Microbiol 2013, 51, 177985.
55. Pai H, Choi EH, Lee HJ, Hong JY, Jacoby GA. Identification of CTX-M-14 extended spectrum β-lactamase in clinical isolates of Shigella sonnei, Escherichia coli, and Klebsiella pneumoniae in Korea. J Clin Microbiol 2001, 39, 3747-3749.
34
-56. Park NY, Na SH, Cho HS. Detection of beta-lactam antibiotics resistant genes in Escherichia coli from porcine fecal samples using DNA chip. Kor J Vet serv 2007, 30, 505-510.
57. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinicalupdate. Clin Microbiol Rev 2005, 18, 657 686.–
58. Ramos UG, Romero EM, Sánchez JS. SHV-type Extended-spectrum ß-lactamase (ESBL) are encoded in related plasmids from enterobacteria clinical isolates from Mexico. Salud Publica Mex 2007, 49, 415-421.
59. Reynaud A, Péduzzi J, Barthélémy M, Labia R. Cefotaxime hydrolyzing activity of the ß-lactamase of Klebsiella oxytoca D488 could be related to a threonine residue at position 140. FEMS Microbiol Lett 1991, 81, 185-192.
60. Sougakoff W, Goussard S, Courvalin P. The TEM-3 ß-lactamase,which hydrolyzes broad-spectrum cephalosporins, is derived from the TEM-2 penicillinase by two amino acid substitutions. FEMS Microbiol Lett 1988, 56, 343-348.
61. Sougakoff W, Goussard S, Gerbaud G. Plasmid-mediated resistance to third-generation cephalosporins caused by point mutations in TEM-type
35
-penicillinase genes. Rev Infect Dis 1988, 10, 879-884.
62. Storberg V. ESBL-producing Enterobacteriaceae in Africa a non-systematic– literature review of research published 2008 2012. Infect Ecol Epidemiol 2014,– 4, 1-16
63. Tumah H. Fourth-generation cephalosporins: in vitro activity against nosocomial gram-negative bacilli. Chemotherapy. 2005, 51, 80-85.
64. Yu WL, Chuang YC, Rasmussen JW. Extended-spctrum beta-lactamases in Taiwan : epidermiology, detection, treatment and infection control. J Microbiol Immunol Infect 2006, 39, 264-277.
36
-β
β
β β
37
